Voyager Acquisition Corp.

What Voyager Acquisition Corp. does

Voyager Acquisition Corp. is a Cayman Islands exempted blank-check company (SPAC) whose sole business purpose is to identify and consummate a merger, share exchange, asset acquisition, share purchase, or reorganization with one or more healthcare-sector targets. The company completed its initial public offering on August 12, 2024, pricing 25,300,000 units at $10.00 on the Nasdaq Global Market (ticker VACHU), raising $253 million in gross proceeds held in trust. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant exercisable at $11.50; the shares and warrants subsequently traded separately under VACH and VACHW. The company operates with a small sponsor team led by President & CEO Adeel Rouf, CFO Alex Rogers, and M.D.-Chairman Warren Hosseinion, with board directors Oded Levy and Jonathan Intrater providing additional healthcare investment and investment-banking expertise.

The company has no products, no operating revenue, and no proprietary technology beyond the SPAC financial vehicle structure itself. Its go-to-market is enterprise field sales in the form of sourcing a single high-quality healthcare target through the management team's professional network. On April 23, 2025, Voyager entered a definitive business combination agreement with VERAXA Biotech AG, a Swiss clinical-stage biopharmaceutical company developing next-generation cancer therapies via its BiTAC platform, at a $1.3 billion pre-money equity value and approximately $1.64 billion implied pro forma equity value. Following VERAXA shareholder approval (99.57% in favor on February 27, 2026) and Voyager shareholder approval on March 12, 2026, the business combination closed on June 10, 2026, with the combined entity commencing Nasdaq trading under VRXA/VRXAW.

A material feature of the de-SPAC outcome is the 99.67% redemption rate by Class A shareholders (25,217,315 of 25,300,000 shares redeemed), leaving only approximately $885,556 in the trust account and 82,685 shares rolling into the combined company. To support closing working capital, Veraxa Biotech Holding AG (PubCo) entered into a $27.5 million senior secured note financing and a $50 million share purchase agreement with Lincoln Park Capital Fund in May 2026. As a result of closing, Voyager Acquisition Corp.'s separate corporate existence effectively ended; the surviving public entity is Veraxa Biotech AG.

Name

Voyager Acquisition Corp.

Legal name

Voyager Acquisition Corporation

Website

https://www.veraxa.com

Company type

Public

Founded year

2017

Operating status

Acquired

Headcount range

11–50 employees

Short description

Voyager Acquisition Corp. was a healthcare-focused Cayman Islands SPAC that raised $253 million in an August 2024 Nasdaq IPO (VACHU) and completed its de-SPAC merger with Swiss clinical-stage oncology biotech VERAXA Biotech AG in June 2026, with the combined entity trading as VRXA.

Ownership category

akta.pro rank

Product category

Special Purpose Acquisition Company (SPAC)

akta.pro primary industry

Capital Markets Advisory (IPO Readiness, SPAC, ECM/DCM Advisory) (BPAHAOAL)

Keywords

• Special purpose acquisition
• Blank check company
• Healthcare mergers
• De-SPAC transactions
• Public capital markets

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Others, Infrastructure

Revenue model

1. Trust Account Returns: As a SPAC, Voyager raised $253 million in its IPO held in trust. The company earns returns on trust funds while searching for an acquisition target. Upon business combination with VERAXA Biotech AG, the remaining ~$885,556 in trust (after 99.67% redemption) was combined with the target company.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Voyager Acquisition Corp. is a healthcare-focused Special Purpose Acquisition Company (SPAC) / blank check company incorporated in the Cayman Islands. Its business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more healthcare-related businesses. The company raised $253 million in its August 2024 IPO and pursued a definitive business combination with VERAXA Biotech AG to create a publicly traded biopharmaceutical company on NASDAQ.

Product overview

Voyager Acquisition Corp. is a healthcare-focused Special Purpose Acquisition Company (SPAC) that completed its IPO in August 2024, raising $253 million. The company does not operate traditional product lines; its core offering is facilitating a business combination transaction. Following the IPO, Voyager entered into a definitive agreement with VERAXA Biotech AG in April 2025 to merge and create a Nasdaq-listed biopharmaceutical company focused on next-generation cancer therapies using the BiTAC platform for antibody-drug conjugates and T-cell engagers. The combined company began trading under ticker VRXA in June 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• SPAC Business Combination Services
• Class A Ordinary Shares (VACH)
• Redeemable Warrants (VACHW)
• VERAXA Biotech Business Combination

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• VERAXA Biotech AGcoreStrategic or Co-development Partner · 23 April 2025Voyager Acquisition Corp. entered into a definitive business combination agreement with VERAXA Biotech AG to create a publicly traded, clinical-stage biopharmaceutical company focused on next-generation cancer therapies. VERAXA's equity value contribution is approximately $1.3 billion, with the combined entity having an implied proforma equity value of approximately $1.64 billion. The transaction was approved by both boards of directors and completed in June 2026, with the combined company trading under symbol VRXA on NASDAQ.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Paya Holdings Inc. Resulting public company (NASDAQ: PAYA) from FinTech Acquisition Corp III's SPAC merger, in which Voyager CEO Adeel Rouf participated. Comparable SPAC-to-public transformation outcome.
• Cardio Diagnostics Inc. Public healthcare company (NASDAQ: CDIO) where Voyager Chairman Warren Hosseinion, M.D. and Director Oded Levy both serve on the board. Comparable healthcare thematic focus with overlapping governance.
• Rubicon Technologies: Public company (NYSE: RBT) resulting from a SPAC merger led by Voyager CEO Adeel Rouf as Founder/CFO, valued at $1.7B. Comparable SPAC-led de-SPAC outcome of significant scale.

Direct peers

• Mana Capital Acquisition Corp: SPAC (NASDAQ: MANA) where Voyager board director Jonathan Intrater served as CEO/Chairman. Directly comparable SPAC vehicle with shared leadership overlap.
• Northern Revival Acquisition Corp: SPAC where Voyager CEO Adeel Rouf previously served as COO. Comparable healthcare-oriented blank check vehicle with shared executive leadership.
• GreenVision Acquisition Corp: Blank check company where Voyager board director Jonathan Intrater served as a board member and audit committee chair. Comparable SPAC structure and governance model.
• FinTech Acquisition Corp III: SPAC where Adeel Rouf served as investment professional, leading to the Paya Inc. (NASDAQ: PAYA) business combination. Comparable SPAC sponsor experience and transaction outcome.
• Zalatoris Acquisition Corp: SPAC (NYSE: TCOA) where Voyager CEO Adeel Rouf served as a board director. Similar blank-check structure targeting business combinations with overlapping management connections.
• Altitude Acquisition Corp: Healthcare-focused blank check company (NASDAQ: ALTU) chaired by Warren Hosseinion, M.D., Voyager's Chairman. Directly comparable SPAC structure, healthcare thesis, and overlapping leadership make it the closest peer.

Emerging players

• ARYA Sciences Acquisition Corp IV: Healthcare/biotech-focused SPAC sponsored by ARYA Sciences Holdings. Comparable healthcare blank-check vehicle targeting biotech business combinations.

Market position

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/voyager-acquisition-corp

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voyager Acquisition Corp.